Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome

Inclusion Criteria: * Male or female with confirmed 22q11DS diagnosis. * Minimum age of 8 years or maximum age of 25 years and 11 months. * Attention difficulties pointed out by parents and/or the participant. * Sufficient verbal expression and comprehension skills to understand and follow instructions based on initial interview. Exclusion Criteria: * Participants younger than 8 years and older that 25 years and 11 months. * Previous adverse experience with MPH * Cardio-vascular diseases including rhythm disorders, severe hypertension, cardiac insufficiency, obliterating cardiac and peripheral arterial disease, preexisting cerebrovascular affections, hemodynamically significant congenital heart defect, channelopathies. * For the naïve group only: corrected QT (QTc) distance at baseline electrocardiogram above 460 milliseconds or elongation at control electrocardiogram (Day 6 of treatment) superior to 30 milliseconds with functional complaint. * Psychiatric affections including anxiety attack, psychic tension or restlessness, manic episode, marked psychotic symptoms, schizophrenia, borderline personality disorder, clinical depression (present or past), suicidal episode, diagnosis or family history of Tourette syndrome, alcohol or drug abuse. * Other somatic affections including hyperthyroid, glaucoma, pheochromocytoma. * Concurrent treatment with monoamine oxidase inhibitors or interruption less than 14 days before beginning of treatment. * Pregnancy or breastfeeding.